⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549692 | 0.74 | — | — | |
| SCHEMBL23829740 | 0.73 | — | — | |
| SCHEMBL28484726 | 0.73 | — | — | |
| SCHEMBL23585058 | 0.71 | EGLN1 (0.35) | — | |
| SCHEMBL1380851 | 0.71 | — | — | |
| SCHEMBL27677423 | 0.71 | — | — | |
| SCHEMBL7522993 | 0.67 | TSHR (0.50) | — | |
| SCHEMBL1122417 | 0.67 | — | — | |
| SCHEMBL21549647 | 0.65 | — | — | |
| SCHEMBL16046967 | 0.65 | GPR55 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809830-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | claimed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | claimed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | claimed |
| CN-114072414-A | Coumarin-modified androgens for the treatment of prostate cancer | 健康研究股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9527866-B2 | Processes for production of intermediates for 2-alkyl cephem compounds | SHIONOGI & CO., LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9242999-B2 | Cephem compound having pyridinium group | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1742947-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108398-A1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-17 | — | — | WO | disclosed |
| EP-0593639-A1 | PYRROLIDINE AND THIAZOLIDINE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME. | RHONE POULENC RORER SA (FR) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993001167-A1 | PYRROLIDINE AND THIAZOLIDINE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1993-01-21 | — | — | WO | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |